Literature DB >> 18718762

Fli1 acts at the top of the transcriptional network driving blood and endothelial development.

Feng Liu1, Maggie Walmsley, Adam Rodaway, Roger Patient.   

Abstract

Blood and endothelium arise in close association during development, possibly from a common precursor, the hemangioblast [1-4]. Genes essential for blood and endothelial development contain functional ETS binding sites, and binding and expression data implicate the transcription factor, friend leukaemia integration 1 (Fli1) [5-10]. However, loss-of-function phenotypes in mice, although suffering both blood and endothelial defects, have thus far precluded the conclusion that Fli1 is essential for these two lineages [11, 12]. By using Xenopus and zebrafish embryos, we show that loss of Fli1 function results in a substantial reduction or absence of hemangioblasts, revealing an absolute requirement. TUNEL assays show that the cells are eventually lost by apoptosis, but only after the regulatory circuit has been disrupted by loss of Fli1. In addition, a constitutively active form of Fli1 is sufficient to induce expression of key hemangioblast genes, such as Scl/Tal1, Lmo2, Gata2, Etsrp, and Flk1. Epistasis assays show that Fli1 expression is induced by Bmp signaling or Cloche, depending on the hemangioblast population, and in both cases Fli1 acts upstream of Gata2, Scl, Lmo2, and Etsrp. Taken together, these results place Fli1 at the top of the transcriptional regulatory hierarchy for hemangioblast specification in vertebrate embryos.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18718762     DOI: 10.1016/j.cub.2008.07.048

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  83 in total

Review 1.  The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis.

Authors:  Yoshihide Asano; Andreea M Bujor; Maria Trojanowska
Journal:  J Dermatol Sci       Date:  2010-07-03       Impact factor: 4.563

2.  Etv2 and fli1b function together as key regulators of vasculogenesis and angiogenesis.

Authors:  Michael P Craig; Viktorija Grajevskaja; Hsin-Kai Liao; Jorune Balciuniene; Stephen C Ekker; Joo-Seop Park; Jeffrey J Essner; Darius Balciunas; Saulius Sumanas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-02-26       Impact factor: 8.311

3.  Common genetic control of haemangioblast and cardiac development in zebrafish.

Authors:  Tessa Peterkin; Abigail Gibson; Roger Patient
Journal:  Development       Date:  2009-03-18       Impact factor: 6.868

4.  BMP-mediated specification of the erythroid lineage suppresses endothelial development in blood island precursors.

Authors:  Candace T Myers; Paul A Krieg
Journal:  Blood       Date:  2013-10-07       Impact factor: 22.113

5.  The dynamics of gene expression in vertebrate embryogenesis at single-cell resolution.

Authors:  James A Briggs; Caleb Weinreb; Daniel E Wagner; Sean Megason; Leonid Peshkin; Marc W Kirschner; Allon M Klein
Journal:  Science       Date:  2018-04-26       Impact factor: 47.728

6.  Tril targets Smad7 for degradation to allow hematopoietic specification in Xenopus embryos.

Authors:  Yangsook Song Green; Sunjong Kwon; Mizuho S Mimoto; Yuanyuan Xie; Jan L Christian
Journal:  Development       Date:  2016-09-15       Impact factor: 6.868

Review 7.  Blood cell generation from the hemangioblast.

Authors:  Christophe Lancrin; Patrycja Sroczynska; Alicia G Serrano; Arnaud Gandillet; Cristina Ferreras; Valerie Kouskoff; Georges Lacaud
Journal:  J Mol Med (Berl)       Date:  2009-10-25       Impact factor: 4.599

8.  Maternal pak4 expression is required for primitive myelopoiesis in zebrafish.

Authors:  Sheran H W Law; Thomas D Sargent
Journal:  Mech Dev       Date:  2012-09-29       Impact factor: 1.882

Review 9.  The biochemistry of hematopoietic stem cell development.

Authors:  P Kaimakis; M Crisan; E Dzierzak
Journal:  Biochim Biophys Acta       Date:  2012-10-12

Review 10.  Signalling pathways that control vertebrate haematopoietic stem cell specification.

Authors:  Wilson K Clements; David Traver
Journal:  Nat Rev Immunol       Date:  2013-05       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.